Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Hyung L. Kim; Eddie Mayerson; Primo N Lara; Edward Messing; Cathy Tangen; Brian M. Shuch; Ulka Vaishampayan

doi:10.1016/j.euf.2019.05.006

Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Hyung L. Kim, Eddie Mayerson, Primo N Lara, Edward Messing, Cathy Tangen, Brian M. Shuch, Ulka Vaishampayan

Hematology and Oncology

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Abstract

Trials SWOG 8949 and EORTC 30947 had the same eligibility criteria and established the role of cytoreductive nephrectomy for metastatic renal cell carcinoma. The more recently published CARMENA trial calls into question the need for cytoreductive nephrectomy. A systematic comparison of CARMENA and SWOG 8949 suggests that cytoreductive nephrectomy may be beneficial for patients receiving immunotherapy but not targeted therapy. The approval of immune checkpoint inhibitors for previously untreated metastatic renal cell carcinoma underlines the need for another randomized phase 3 trial of cytoreductive nephrectomy for patients receiving powerful modern immunotherapies.

Original language	English (US)
Journal	European Urology Focus
DOIs	https://doi.org/10.1016/j.euf.2019.05.006
State	Published - Jan 1 2019

Keywords

cytoreductive nephrectomy
immunotherapy
metastatic renal cell carcinoma

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.euf.2019.05.006

Fingerprint Dive into the research topics of 'Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this

@article{c71d7e4576b5492a822573b9b5a4e61b,

title = "Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma",

abstract = "Trials SWOG 8949 and EORTC 30947 had the same eligibility criteria and established the role of cytoreductive nephrectomy for metastatic renal cell carcinoma. The more recently published CARMENA trial calls into question the need for cytoreductive nephrectomy. A systematic comparison of CARMENA and SWOG 8949 suggests that cytoreductive nephrectomy may be beneficial for patients receiving immunotherapy but not targeted therapy. The approval of immune checkpoint inhibitors for previously untreated metastatic renal cell carcinoma underlines the need for another randomized phase 3 trial of cytoreductive nephrectomy for patients receiving powerful modern immunotherapies.",

keywords = "cytoreductive nephrectomy, immunotherapy, metastatic renal cell carcinoma",

author = "Kim, {Hyung L.} and Eddie Mayerson and Lara, {Primo N} and Edward Messing and Cathy Tangen and Shuch, {Brian M.} and Ulka Vaishampayan",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/j.euf.2019.05.006",

language = "English (US)",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

AU - Kim, Hyung L.

AU - Mayerson, Eddie

AU - Lara, Primo N

AU - Messing, Edward

AU - Tangen, Cathy

AU - Shuch, Brian M.

AU - Vaishampayan, Ulka

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Trials SWOG 8949 and EORTC 30947 had the same eligibility criteria and established the role of cytoreductive nephrectomy for metastatic renal cell carcinoma. The more recently published CARMENA trial calls into question the need for cytoreductive nephrectomy. A systematic comparison of CARMENA and SWOG 8949 suggests that cytoreductive nephrectomy may be beneficial for patients receiving immunotherapy but not targeted therapy. The approval of immune checkpoint inhibitors for previously untreated metastatic renal cell carcinoma underlines the need for another randomized phase 3 trial of cytoreductive nephrectomy for patients receiving powerful modern immunotherapies.

AB - Trials SWOG 8949 and EORTC 30947 had the same eligibility criteria and established the role of cytoreductive nephrectomy for metastatic renal cell carcinoma. The more recently published CARMENA trial calls into question the need for cytoreductive nephrectomy. A systematic comparison of CARMENA and SWOG 8949 suggests that cytoreductive nephrectomy may be beneficial for patients receiving immunotherapy but not targeted therapy. The approval of immune checkpoint inhibitors for previously untreated metastatic renal cell carcinoma underlines the need for another randomized phase 3 trial of cytoreductive nephrectomy for patients receiving powerful modern immunotherapies.

KW - cytoreductive nephrectomy

KW - immunotherapy

KW - metastatic renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85065540051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065540051&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.05.006

DO - 10.1016/j.euf.2019.05.006

M3 - Comment/debate

C2 - 31103605

AN - SCOPUS:85065540051

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -